Business Context and Reporting Period
Company: FibroGen, Inc. (FGEN)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Business Overview: FibroGen is a biopharmaceutical company developing novel therapies for cancer and anemia. Its lead assets include roxadustat (approved in China, Europe, and Japan for anemia in chronic kidney disease) and FG-3246 (an antibody-drug conjugate in Phase 1/2 for metastatic castration-resistant prostate cancer).
Strategic Shift: On February 20, 2025, the company entered into an agreement to sell FibroGen International (its China operations) to AstraZeneca Treasury Limited for approximately $160 million. Consequently, China operations are classified as discontinued operations.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue (Continuing Ops) | $29.6 million | $46.8 million |
| Loss from Continuing Operations | $(153.1) million | $(323.0) million |
| Net Loss (Including Discontinued Ops) | $(47.6) million | $(284.2) million |
| Cash and Cash Equivalents (Continuing Ops) | $50.5 million | $81.6 million |
| Accumulated Deficit | $(1.89) billion | $(1.84) billion |
| Debt Obligations | $73.1 million (Senior Secured Term Loan) | $71.9 million |
| Liability Related to Sale of Future Revenues | $59.3 million | $57.1 million |
Note: Discontinued operations (China) generated $105.5 million in income for 2024, significantly offsetting the loss from continuing operations.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue from continuing operations decreased 37% to $29.6 million. This was driven by a 100% drop in license revenue and an 89% drop in development revenue, partially offset by a 48% increase in drug product revenue due to a $25.7 million catch-up adjustment from the termination of the AstraZeneca U.S./RoW agreement.
- Expense Reduction: Total operating costs and expenses decreased 51% to $180.0 million. Key drivers included:
- $61.4 million reduction in clinical trial expenses following the termination of the pamrevlumab program.
- $51.5 million reduction in employee-related expenses due to a 75% reduction in the U.S. workforce.
- $24.6 million one-time non-cash charge in 2023 for acquired in-process R&D (not present in 2024).
- Restructuring: A $19.5 million restructuring charge was recorded in 2024 (vs. $12.6 million in 2023) related to the U.S. workforce reduction.
- Asset Disposal: The company disposed of all property and equipment in 2024 as part of streamlining operations.
Guidance, Outlook, and Risks
Going Concern Warning
Management has determined there is substantial doubt about the company's ability to continue as a going concern within 12 months of the filing date. The company relies on the closing of the FibroGen International sale to AstraZeneca to access approximately $51.7 million in cash held in China and to repay its senior secured term loan. Without this transaction or additional capital raising, the company may not have sufficient liquidity to fund U.S. operations or comply with debt covenants requiring a minimum of $30 million in unrestricted U.S. cash.
Outlook and Pipeline
- Roxadustat (MDS): The company plans to meet with the FDA in Q2 2025 to discuss the path forward for roxadustat in myelodysplastic syndromes (MDS).
- FG-3246: A Phase 2 monotherapy dose optimization study for metastatic castration-resistant prostate cancer is anticipated to initiate in mid-2025.
- China Sale: The sale of FibroGen International is expected to close by mid-2025, subject to regulatory approval.
Key Risks
- Delisting Risk: The company received notice from Nasdaq that it failed to regain compliance with the minimum bid price rule ($1.00). An appeal was filed on March 14, 2025, staying delisting pending a ruling.
- Generic Competition: In China, eight generic versions of roxadustat have been approved. A national tender (Volume-Based Purchasing) is expected in H1 2025, which could significantly reduce pricing and revenue.
- Intellectual Property: Several roxadustat patents in Europe and China are currently under challenge or have been revoked on appeal.
- Legal Proceedings: The company is subject to an ongoing SEC investigation regarding roxadustat cardiovascular safety data and derivative lawsuits. A securities class action was settled for $28.5 million (fully covered by insurance).
Investor Verification Checklist
- Closing of China Sale: Verify the status of the AstraZeneca acquisition of FibroGen International, as this is critical for liquidity and debt covenant compliance.
- Nasdaq Compliance: Monitor the outcome of the Nasdaq Hearings Panel appeal regarding the minimum bid price deficiency.
- Debt Covenants: Confirm the company maintains the required $30 million unrestricted cash balance in the U.S. to avoid default on the Morgan Stanley term loan.
- China Pricing: Track the timing and outcome of the anticipated Volume-Based Purchasing (VBP) tender for roxadustat in China.
- SEC Investigation: Monitor updates on the resolution of the SEC inquiry regarding roxadustat safety data.